Foghorn Therapeutics Inc (FHTX)
6.11
+0.26
(+4.44%)
USD |
NASDAQ |
Jun 03, 16:00
6.11
0.00 (0.00%)
After-Hours: 16:24
Foghorn Therapeutics Debt to Equity Ratio: 0.00 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.2459 |
| June 30, 2021 | 0.1903 |
| March 31, 2021 | 0.1577 |
| December 31, 2020 | 0.1344 |
| September 30, 2020 | -0.1109 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.1109
Minimum
Sep 2020
0.2459
Maximum
Sep 2021
0.0412
Average
--
Median
Dec 2021
Debt to Equity Ratio Benchmarks
| Viridian Therapeutics Inc | 0.0349 |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.5332 |
| IGC Pharma Inc | 0.0152 |
| NovaBay Pharmaceuticals Inc | 6.294 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 255.00M |
| Total Liabilities (Quarterly) | 352.49M |
| Shareholders Equity (Quarterly) | -97.49M |
| Current Ratio | 4.063 |